- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Interventions
- bempedoic acid
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 122
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 26
- States / cities
- Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
- Interventions
- CTX310
- Drug
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- Kinetics test
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Evinacumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Wilmington, Delaware • Boca Raton, Florida • Kansas City, Kansas + 3 more
- Conditions
- Myocardial Infarction, Hypercholesterolemia
- Interventions
- alirocumab, placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 14
- States / cities
- Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
- Conditions
- Atherosclerosis, Coronary Artery Disease
- Interventions
- lovastatin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 21 Years to 67 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1985 – 1992
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Cascade screening
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
- Interventions
- mipomersen sodium
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
- Conditions
- Heterozygous Familial Hypercholesterolemia, Non-familial Hypercholesterolemia
- Interventions
- Praluent
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 57
- States / cities
- Auburn, Alabama • Mobile, Alabama • Beverly Hills, California + 50 more
- Conditions
- Heterozygous or Homozygous Familial Hypercholesterolemia
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more
- Conditions
- Lysosomal Acid Lipase Deficiency
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
- Interventions
- ETC-1002, Placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Implitapide
- Drug
- Lead sponsor
- Medical Research Laboratories International
- Industry
- Eligibility
- 8 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Not listed
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Rosuvastatin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more
- Conditions
- Hypercholesterolemia, Heterozygous Familial
- Interventions
- mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 20
- States / cities
- Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Severe Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more
- Conditions
- Hyperlipidemias
- Interventions
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
- Combination Product · Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Testing centralized referral mechanism for PCPs, Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Daphne, Alabama • Boca Raton, Florida • Cutler Bay, Florida + 10 more